NYSE:GKOSMedical Equipment
A Look At Glaukos (GKOS) Valuation As Epioxa Showcased At ASCRS Annual Meeting
Glaukos (GKOS) is back on investors’ radar as the company prepares to showcase its ophthalmic technologies at the ASCRS annual meeting in Washington, including an educational symposium introducing its FDA-approved Epioxa corneal cross-linking treatment.
See our latest analysis for Glaukos.
The recent ASCRS spotlight appears to align with strong momentum, with a 1 day share price return of 3.48% at US$116.69, a 7 day share price return of 11.12%, and a 1 year total shareholder return of 35.58%...